Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions
Interventions
Bevacizumab
Cyclophosphamide
+2 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
September 1, 2016
Primary Completion Date
June 27, 2019
Completion Date
June 30, 2021
Last Updated
October 6, 2021
NCT04919629
NCT01167712
NCT04739800
NCT02111941
NCT02713386
NCT03924245
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions